BACKGROUND: Bone marrow mesenchymal stem cells (BMSCs) in a specific environment can divide into hepatic stem cells and liver cells, which can participate in repair and reconstruction of liver structure and function.
OBJECTIVE: To explore the safety, feasibility and therapeutic effect of autologous BMSCs after culture transplantation via hepatic artery in treatment of cirrhosis.
METHODS: One patient with cirrhosis received autologous bone marrow mononuclear cell transplantation. Bone marrow mononuclear cells were isolated from autologous bone marrow and purified in vitro, and then cultured after 4 days. The stem cells were transplanted into the liver via hepatic artery. At 4 week after transplantation, serum albumin (ALB), cholinesterase (CHE), prothrombin activity (PTA), total bilirubin level (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), fibrinogen changes and complications and prognosis were observed.
RESULTS AND CONCLUSION: Numbers of BMSCs were significantly increased after culture. The index changes were respectively observed before and after transplantation. Pre-transplant: ALB, CHE, PTA, ALT, AST, PT, and fibrinogen were respectively 29. 43 g/L, 2 378.5 U/L, 47. 4%, 112.78 U/L, 79.36 U/L, 17.91 s, 2.01 g/L; 4 week after transplantation: 33.30 g/L, 2 866. 5 U/L, 55. 8%, 79.01U/L, 56.37 U/L, 16.26 s, and 2.35 g/L. No adverse event occurred following transplantation. Results suggest that after transplantation of autologous bone marrow, the liver function of patients was significantly improved. This method was safe and effective in the treatment of patients with decompensated cirrhosis. It can be used as a clinical treatment in patients with middle and advanced stage cirrhosis.